Pretreatment with Antiviral Preparation Kagocel Normalizes the Content of Bone Marrow Multipotent Stromal Cells and TNFα in Blood Serum of CBA Mice Disturbed by Administration of S. typhimurium Antigen Complex In Vivo and Maintains High Concentration of IL-10 and Th1 Cytokines
- Авторлар: Gorskaya Y.1, Suslov A.2, Semenova E.1, Konopleva M.2, Nesternko V.1
-
Мекемелер:
- Laboratory for Regulation of Immunity and Immunological Tolerance
- Laboratory of Mediators and Effectors of Immunity, N. F. Gamaleya Federal Research Center for Epidemiology and Microbiology, Ministry of the Healthcare of the Russian Federation
- Шығарылым: Том 163, № 6 (2017)
- Беттер: 761-765
- Бөлім: Article
- URL: https://journals.rcsi.science/0007-4888/article/view/239239
- DOI: https://doi.org/10.1007/s10517-017-3898-4
- ID: 239239
Дәйексөз келтіру
Аннотация
Pretreatment with the active substance of antiviral preparation Kagocel, inductor of type I endogenous IFN, in a daily therapeutic dose (30 μg/mouse) 3 h prior to administration of S. typhimurium antigens to CBA mice reduced the number of bone marrow multipotent stromal cell (significantly increased by 3.2 times on the next day after antigen injection) to the initial level. Thus, activation of the stromal tissue induced by administration of the bacterial antigen was blocked. In addition, preliminary administration of Kagocel modulated the cytokine profile of the blood serum affected by S. typhimurium antigens: reduced 1.6-fold elevated concentration a proinflammatory cytokine TNFα to the control level (in 4 h after antigen injection) and maintained this level in 20 h after antigen administration. Kagocel also maintained the concentration of anti-inflammatory cytokine IL-10 at the level surpassing the normal by 1.6 times and high concentrations of Th1 cytokines (IL-2, IFNγ, and IL-12). These results suggest that Kagocel can reduce the immune response to bacterial antigens (similar to type I IFN [7]), which can contribute to its therapeutic and preventive effects in addition to its well documented antiviral activity and then this preparation can be used for the therapy of diseases accompanied by excessive or chronic inflammation.
Авторлар туралы
Yu. Gorskaya
Laboratory for Regulation of Immunity and Immunological Tolerance
Хат алмасуға жауапты Автор.
Email: uliya.gorskaya@nearmedic.ru
Ресей, Moscow
A. Suslov
Laboratory of Mediators and Effectors of Immunity, N. F. Gamaleya Federal Research Center for Epidemiology and Microbiology, Ministry of the Healthcare of the Russian Federation
Email: uliya.gorskaya@nearmedic.ru
Ресей, Moscow
E. Semenova
Laboratory for Regulation of Immunity and Immunological Tolerance
Email: uliya.gorskaya@nearmedic.ru
Ресей, Moscow
M. Konopleva
Laboratory of Mediators and Effectors of Immunity, N. F. Gamaleya Federal Research Center for Epidemiology and Microbiology, Ministry of the Healthcare of the Russian Federation
Email: uliya.gorskaya@nearmedic.ru
Ресей, Moscow
V. Nesternko
Laboratory for Regulation of Immunity and Immunological Tolerance
Email: uliya.gorskaya@nearmedic.ru
Ресей, Moscow